The Effect of Resveratrol or Curcumin on Head and Neck Cancer Cells Sensitivity to the Cytotoxic Effects of Cisplatin

Natural compounds can modulate all three major phases of carcinogenesis. The role of the natural compounds such as resveratrol (RSV) and curcumin (CRM) in modulation of anticancer potential of platinum-based drugs (CisPt) is still a topic of considerable debate. In order to enhance head and neck cancer (HNSCC) cells’ sensitivity to the cytotoxic effects of CisPt combined treatments with RSV or CRM were used. The study aim was to evaluate how the RSV or CRM associated to CisPt treatment modulated some cellular processes such as proliferation, P21 gene expression, apoptotic process, and cell cycle development in HNSCC tumor cell line (PE/CA-PJ49) compared to a normal cell line (HUVEC). The results showed that RSV or CRM treatment affected the viability of tumor cells more than normal cells. These natural compounds act against proliferation and sustain the effects of cisplatin by cell cycle arrest, induction of apoptosis and amplification of P21 expression in tumor cells. In conclusion, using RSV or CRM as adjuvants in CisPt therapy might have a beneficial effect by supporting the effects induced by CisPt.

Cisplatin effect on head and neck squamous cell carcinoma cells is modulated by ERK1/2 protein kinases

The extracellular signal-regulated kinases (ERKs) are key transducers of the extracellular signals into intracellular responses and represent major molecular players in tumorigenesis. The aim of this study was to determine how curcumin (CRM) used as an adjuvant supports the apoptotic process induced by a single chemical agent treatment (cisplatin-CisPT) on two head and neck squamous cell carcinoma cell lines (FaDu and PE/CA-PJ49) and the involvement of ERK1/2 and/or p53 activation in this process. Data have shown that the CisPt effect is potentiated by CRM. CRM induced an increase of p53 protein phosphorylation in both cell lines. CisPt decreased p53 protein phosphorylation in FaDu cells, but increased it in PE/CA-PJ49 cells. Data showed that the constitutive expression of activated ERK1/2 protein-kinase was different in the two analyzed tumor cell lines. ERK1/2 activation status was essential for both cell processes, proliferation and apoptosis induced by CisPt and/or CRM treatment on squamous cell carcinoma cells. Our data suggest that p53 phosphorylation in the apoptotic process induced by CRM treatment might require the involvement of ERK1/2. In this regard the CisPt treatment suggested that p53 phosphorylation is ERK1/2 independent in FaDu cells having a p53 gene deletion and ERK1/2 dependent in PE/CA-PJ49 cells having a p53 gene amplification. Moreover, in both tumor cell lines our results support the involvement of p53 phosphorylation-ERK1/2 activation-dependent in the apoptosis induced by combined treatments (CisPt and CRM). The use of CRM as adjuvant could increase the efficiency of chemotherapy by modulating cellular activation processes of ERK1/2 signaling pathways. In conclusion, the particular mode of intervention by which ERK1/2 might influence cell proliferation and/or apoptosis processes depends on the type of therapeutic agent, the cells' particularities, and the activation status of the ERK1/2.

Characterization of the tumor cells from human head and neck cancer

Although it is very difficult to establish a correlation between the behavior of tumor cells in vitro and in vivo tumors, in this study we tried to analyze some functions of the tumor cells isolated from head and neck tumor fragments, comparatively with the tumor cell cultures, hoping that the results could help the clinician to choose optimal treatment for head and neck cancer patients. The aim of the present study was to evaluate the expression of p53 protein, the apoptosis process and the cell cycle parameters in the cell cultures of head and neck carcinoma obtained from fragments of tumor excised from patients. Using ELISA assay and flow cytometry methods we analyzed the p53 protein expression, distribution of the cell cycle phases and the level of apoptosis in the tumor cells which were immediately isolated from the tumor fragments, as well as in the ones that were subsequently passed in culture several times. Our results showed that p53 protein expression was weak in four (33.3%) patients, moderate in three (25%) patients and intense in five (41.6%) patients. Our data showed that both tumor cells isolated from the tumor fragments (passage 0), as well as cell cultures at passage 5 had the percentage of S-phase of the cellular cycle higher than 20%, suggesting that tumors have high proliferative activity. The tumor cells cultures have a small percentage of apoptosis that may reflect a biological aggressive tumor character. In conclusion, these data may improve the diagnostic protocols and help to an efficient monitoring of therapy.